Watch MBX. Know when insiders buy.
One email the day a filing lands. Free.
MBX
MBX Biosciences, Inc.
53.93
+0.43 +0.80%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
98
PASS · shorts 98
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.6BP/E —DIV YIELD —FCF YIELD -3.28%REV TTM —NET INCOME −$104.3MNET CASH —52W 14.78 – 70.70SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$40.9M | −$37.1M | — | -0.78 | −$22.6M | $901K | −$23.5M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$27.3M | −$23.5M | — | -0.50 | −$20.2M | $437K | −$20.6M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$25.8M | −$22.1M | — | -0.45 | −$18.3M | $793K | −$19.1M | Aug 6 |
| Q3 2025 · Sep 30 | — | — | — | −$23.9M | −$21.6M | — | -0.63 | −$21.5M | $399K | −$21.9M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$21.8M | −$19.4M | — | -0.58 | −$17.4M | $707K | −$18.1M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$26.5M | −$23.9M | — | -0.71 | −$22.7M | $30K | −$22.7M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$18.6M | −$15.6M | — | 9.60 | −$16M | $92K | −$16.1M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$19.6M | −$18.1M | — | -2.78 | −$14.7M | $57K | −$14.7M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$16.7M | −$15.9M | — | -12.62 | −$13.3M | $452K | −$13.7M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$13.3M | −$12.3M | — | -10.26 | −$10.7M | $273K | −$11M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$10M | −$8.8M | — | -7.68 | −$11.1M | $55K | −$11.2M | Mar 17 |
| Q3 2023 · Sep 30 | — | — | — | −$10.9M | −$10.2M | — | -9.40 | — | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$98.1M | −$87M | — | -2.38 | −$79.9M | $1.9M | −$81.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$68.2M | −$61.9M | — | -5.82 | −$54.7M | $874K | −$55.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$35.3M | −$32.6M | — | -31.96 | −$32M | $129K | −$32.1M | — | — |
Every number comes from MBX Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.